We are live on ! Find out more

AARD

Aardvark Therapeutics

AARD

Market cap $149M

6.82 USD

+0.93

15.79%

At close Updated Aug 21, 4:00 PM EDT

1 day

15.79%

5 days

4.28%

1 month

12.17%

3 months

51.22%

6 months

-45.79%

Year to date

-48.29%

1 year

-29.91%

5 years

-52.34%

10 years

-52.34%

About: Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Employees: 28

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AARD

New York, New York--(Newsfile Corp. - August 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AARD

AARD INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 13, 2025 (the "IPO" or "Offering"); and/or (b) Aardvark securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - August 23, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) and reminds investors of the October 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

AARD INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026

ROSEN, A LONGSTANDING FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AARD

New York, New York--(Newsfile Corp. - August 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, A LONGSTANDING FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AARD

ROSEN, RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD

NEW YORK, Aug. 21, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Aardvark's February 13, 2025 initial public offering (“IPO”); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 13, 2026.

ROSEN, RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD

Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit

San Francisco, California--(Newsfile Corp. - August 21, 2026) - Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit. Investors who purchased or acquired Aardvark common stock pursuant and/or traceable to the offering documents issued in connection with the Company's initial public offering (IPO) on or about February 13, 2025, and/or purchased or acquired Aardvark securities between February 13, 2025 and May 14, 2026 (the Class Period), are encouraged to contact our firm now.

Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit

Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD

NEW YORK, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) and certain officers and directors.   The class action, filed in the United States District Court for the Southern District of California, and docketed under 26-cv-04643, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 13, 2025 (the “IPO” or “Offering”); and/or (b) Aardvark securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”).

Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD

Law Offices of Frank R. Cruz Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire About Securities Fraud Class Action

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire About Securities Fraud Class Action.

Law Offices of Frank R. Cruz Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire About Securities Fraud Class Action

Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD

LOS ANGELES--(BUSINESS WIRE)---- $AARD--Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD.

Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $AARD--AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law.

AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

LAWSUIT ALERT: Investors who lost over $100,000 with Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 2025 and May 2026, should contact the Shareholders Foundation

SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- The Shareholders Foundation, Inc. announces that a deadline is coming up on October 31, 2026, in the lawsuit that was filed for certain investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD). Investors, who purchased shares in excess of $100,000 of Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 13, 2025 and May 14, 2026, have certain options and there are short and strict deadlines running.

LAWSUIT ALERT: Investors who lost over $100,000 with Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 2025 and May 2026, should contact the Shareholders Foundation

See News Rankings

Price charts implemented using Lightweight Charts™